Biology has solutions for our world’s problems. We enable them.

We harness the power of evolution to create unique, commercial products by engineering the genomes of microbes.
who we are

Colin South


Colin R. South, Ph.D., is an experienced executive, entrepreneur, and leader. He has broad experience in the emerging bioprocess sector, having founded and held senior technical and operational leadership positions in companies across the life sciences, nutrition, agricultural, and energy sectors. His senior roles include: CEO at Proterro Inc., Novogy Inc., and ViaLactia Biosciences, and President & Chief Strategic Officer of Mascoma Corp. Dr. South has an undergraduate degree in Chemical Engineering from the University of Canterbury in Christchurch, New Zealand, a Masters in Engineering Management, and a PhD in Bioprocess Engineering from Dartmouth College.

Jay Konieczka

COO, Co-founder, Director

Jay H Konieczka PhD, is cofounder and Chief Operating Officer. He overseas enEvolv's R&D operations and external collaborations. Prior to enEvolv, Dr. Konieczka was a Postdoctoral Fellow at Harvard University and The Broad Institute where he combined experimental and computational approaches in genome analysis. He has extensive experience in comparative functional genomics and molecular genetics. Dr. Konieczka received bachelors degrees in Computer Science and Evolutionary Biology from the University of Texas at Austin, and a PhD in Molecular & Cellular Biology from the University of Arizona.

Ginja Tavares da Silva


Ginja Tavares da Silva, has more than 20 years of experience in accounting, finance and entrepreneurship. She was a Co-Founder and Vice President of Finance for Novogy, Inc. and has held positions as Senior Vice President of Finance at Mascoma Corporation; Vice President of Finance, Treasurer and Corporate Secretary of VeraSun Energy, Vice President and Associate with Conifer Investments, LLC; and as an Analyst with U.S. Bancorp and Standard Insurance Company. She has placed over $1.3 billion in renewable fuels financing and led the IPO and listing on the NYSE for VeraSun, the first dedicated corn ethanol company. Ms. Silva received a AB degree in Economics and Mathematics from Smith College.

George Church


George M. Church, Ph.D., is a distinguished Professor of Genetics and Director of the Center for Computational Genetics at Harvard Medical School. Dr. Church is widely regarded as a pioneer in personal genomics and synthetic biology, having authored and co-authored more than 270 publications and 50 patents. His 1984 Harvard PhD included the first direct genomic sequencing method. He invented the broadly applied concepts of molecular multiplexing and tags, homologous recombination methods, and array DNA synthesizers. He helped initiate the Human Genome Project in 1984 and initiated the Personal Genome Project (PGP) in 2005. His many innovations in genomics, computational biology, genetics, and systems and synthetic biology have been the basis for a number of companies. He is director of the NIH CCV Center for Excellence in Genomic Science and director of the U.S. Department of Energy Center on Bioenergy at Harvard & MIT. He is a Hoogendijk Prize awardee, a Franklin Laureate for Achievement in Science, and a member of the National Academy of Sciences and the National Academy of Engineering.

Farren Isaacs

Co-founder & Director

Farren J. Isaacs, Ph.D., is an Associate Professor of Molecular, Cellular and Developmental Biology at Yale University. He received a B.S.E degree in Bioengineering from the University of Pennsylvania and obtained his Ph.D. from the Biomedical Engineering Department and Bioinformatics Program at Boston University. In his Ph.D. he pioneered the design and development of synthetic RNA components capable of probing and programming cellular function. He then was a research fellow in the Department of Genetics at Harvard Medical School working on genome engineering technologies with George Church. At Harvard, he developed enabling technologies for genome engineering, including MAGE (Multiplex Automated Genome Engineering) and CAGE (Conjugative Assembly Genome Engineering). His research is focused on developing foundational genomic and biomolecular engineering technologies with the goal of developing new genetic codes, and engineered cells that serve as factories for chemical, drug and biofuel production. He has recently been named a “rising young star of science” by Genome Technology Magazine and a Beckman Young Investigator by the Arnold and Mabel Beckman Foundation.

Charles Cooney


Charles L. Cooney, Ph.D., is the Robert T. Haslam (1911) Professor of Chemical and Biochemical Engineering in the Department of Chemical Engineering at MIT and the Faculty Director of the Deshpande Center for Technological Innovation. He received his Bachelor’s degree in Chemical Engineering from the University of Pennsylvania, Master’s and Ph.D. in Biochemical Engineering from MIT. He has received multiple awards and more recently elected (2009) to the first class of American Chemical Society Fellows. In July 2012 he was awarded Honoris Causa by Ramon Llull University in Barcelona. He serves as a consultant to a number of biotech and pharmaceutical companies, is on multiple editorial boards of professional journals, sits on the Boards of Directors of Polypore International, Inc., LS9, Inc., Mitra (India), GreenLight Bioscience, Pronutria, Inc. and Biocon, Ltd (India) and was previously on the Boards of Genzyme, Cuno, Inc., Pall Corp. and Astra AB. He chaired the FDA Advisory Committee for Pharmaceutical Science from 2004-2006. Professor Cooney’s research interests include manufacturing in the pharmaceutical, biotech and bioprocess industries, as well as bioprocess design, operation and control, and processing of pharmaceutical powders and technological innovation strategy. As founding faculty director of the Deshpande Center he is interested in the process of stimulating technological innovation and translating innovation into new company creation.

Ron Meeusen


Ronald L. Meeusen, Ph.D., is a Managing Director of Cultivian Sandbox and co-founder and Managing Partner of Cultivian Ventures. Ron has over 30 years of experience in bringing new technologies and products to market. He has led research and development for major corporations in agricultural chemicals, field crop and vegetable genetics and breeding, animal health, novel foods and industrial materials. His successful projects include the world's first field trial of a genetically engineered crop trait in 1986, development and launch of one of the first insect and herbicide resistant corn hybrids in 1996, introduction of a trans-fat free canola oil, and development of dozens of new varieties of field and vegetable crops on three continents. Ron has been a frequent speaker at conferences, a consultant to Federal policy on biotechnology regulatory issues, and active in industry trade groups. Prior to forming Cultivian Ron led the expansion of the biotechnology research and development program of Dow AgroSciences, and founded a successful biopharmaceutical company, Immuneworks, Inc. Ron represents Cultivian on the board of directors of AbCelex Technologies, Agrivida, enEvolv, Proterro, Rivertop Renewables, Vestaron and Virgin Plants. He was also a member of the board of directors of Allylix, Aratana Therapeutics and Divergence, Inc. Ron holds a Ph.D. from the University of California, Berkeley in plant cell biology, and a bachelor's degree from the University of Wisconsin, Milwaukee in plant physiology.

James Barber


James J. Barber, Ph.D., has extensive experience in industrial biotechnology, having most recently served as President and CEO of Metabolix, Inc. Under his leadership, Metabolix developed the Mirel™ line of bioplastics and formed Telles™, a joint venture with Archer Daniels Midland (ADM). Dr. Barber also led Metabolix through a successful IPO in November 2006. Prior to Metabolix, Dr. Barber served as Global Business Director for Albemarle Corporation, with global P&L responsibility for that $100+ million business. He also served as Director of Business Development with Ethyl Corporation, with responsibility for acquisitions and managing Ethyl's venture capital activities. Dr. Barber received a B.S. degree in Chemistry from Rensselaer Polytechnic Institute in 1976 and a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology in 1980. He received the American Chemical Society's Henry F. Whalen, Jr. award for Business Development in September of 2003. Dr. Barber serves on the Advancement Council of the College of Polymer Science and Polymer Engineering at the University of Akron, as a director of Graham Corporation, Agrivida, and Segetis, and as chairman of the board of Allylix.

James Collins


James J. Collins, Ph.D., is one of the founders of synthetic biology, and a pioneering researcher in systems biology, having made fundamental discoveries regarding the actions of antibiotics and the emergence of antibiotic resistance. He is the Henri Termeer Professor of Medical Engineering & Science and Professor of Biological Engineering at MIT and a Howard Hughes Medical Institute (HHMI) Investigator. He is also a core founding faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University. He is a Fellow of the American Physical Society, the Institute of Physics, and the American Institute for Medical and Biological Engineering. Collins was elected to the National Academy of Engineering, the American Academy of Arts and Sciences, and the Institute of Medicine of the National Academy of Sciences. Professor Collins' scientific accomplishments have been recognized by numerous awards. In 2003, he received a MacArthur Foundation "Genius Award", becoming the first bioengineer to receive this honor. He has also received the NIH Director's Pioneer Award, the Ellison Medical Foundation Senior Scholar Award in Aging, the inaugural Anthony J. Drexel Exceptional Achievement Award, the Lagrange Prize from the CRT Foundation in Italy, being selected for Technology Review's inaugural TR100 (100 young innovators who will shape the future of technology), and the Scientific American 50 (the top 50 outstanding leaders in science and technology).

David Rudner


David Z. Rudner, Ph.D., is a professor in the Department of Microbiology and Immunobiology at Harvard Medical School. Work in his laboratory focuses on fundamental questions in bacterial cell biology and development, i.e., how information is transduced across a lipid bilayer, how replicated chromosomes are organized and segregated, as well as how the cell envelope is remodeled during growth and differentiation. His group addresses these questions in the bacterium Bacillus subtilis, taking advantage of the developmental process of spore formation in this organism. Additionally, he investigates the mechanisms underlying cell envelope biogenesis in the Gram-positive pathogens Staphylococcus aureus and Streptococcus pneumoniae.